Related Experiment Videos

Impact of obesity on 1-year major adverse cardiac events after primary PCI for STEMI

Lisa Simioni1, Tania Loureiro2, Yannick Faucherre1

  • 1Cardiology, University and Hospital Fribourg, Switzerland.

Insights

Obesity did not increase major adverse cardiovascular events (MACE) in ST-segment elevation myocardial infarction (STEMI) patients after percutaneous coronary intervention (PCI). However, obese patients experienced longer in-hospital delays but similar clinical outcomes.

Area of Science:

  • Cardiology
  • Obesity Research
  • Public Health

Background:

  • Rising obesity rates in Switzerland necessitate understanding its impact on cardiovascular health.
  • The "obesity paradox" suggests potential protection against major adverse cardiovascular events (MACE) post-ST-segment elevation myocardial infarction (STEMI).

Purpose of the Study:

  • To evaluate the association between obesity and MACE in STEMI patients undergoing percutaneous coronary intervention (PCI).

Main Methods:

  • Retrospective analysis of the Fribourg STEMI Fast-Track registry.
  • Classification of adult patients into obese (BMI ≥ 30 kg/m²) and non-obese (BMI < 30 kg/m²) groups.
  • 12-month follow-up for composite MACE, including death, recurrent acute coronary syndrome (ACS), stroke, stent thrombosis, revascularization, and major bleeding (BARC 3-5).

Main Results:

  • Obesity was not associated with a higher 1-year MACE rate after PCI in STEMI patients.
  • Obese patients had longer first medical contact-to-revascularization times but similar overall ischemic times.
  • Differences observed in patient presentation and pre-hospital care pathways, but not in clinical outcomes.

Conclusions:

  • Obesity does not adversely affect 1-year MACE rates in STEMI patients treated with primary PCI.
  • Obesity is linked to altered care pathways and increased in-hospital delays, without impacting clinical outcomes.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...